Brasília – The Ministry of Health and the National Health Surveillance Agency (Anvisa) have designated absolute priority to the clinical study of polilaminin, a treatment developed by researchers at the Federal University of Rio de Janeiro (UFRJ) for spinal cord injuries. The announcement was made by Health Minister Alexandre Padilha, who said the government’s goal is to accelerate the evaluation and potential incorporation of the drug into the Unified Health System (SUS).

Developed in partnership with the pharmaceutical company Cristália, polilaminin is derived from a placenta-based protein and has shown promising results in laboratory and early human studies, promoting neural regeneration and partial recovery of motor functions. The company is now awaiting authorization from Anvisa to begin Phase I clinical trials in patients with acute spinal cord trauma.

According to the Ministry of Health, the decision reflects a broader effort to prioritize studies with high social and scientific impact, especially those that could address conditions without effective treatments. The case has drawn national attention for its potential to mark a breakthrough in neurological rehabilitation and expand Brazil’s capacity for advanced therapy research.

Source: O Globo

Would you like a complete analysis on this? Contact us at pharmabrnews@gmail.com